This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hsu, L.-C. Search for Related Content PubMed PubMed Citation Articles by Hsu, L.-C. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Hazardous Substances DB HEPARIN Social Bookmarking                         What's this?

Heparin-coated cardiopulmonary bypass circuits: current status

Edwards Lifesciences LLC, Irvine, California, LCHsu{at}therox.com

Heparin-coated circuits have been subjected to vigorous testing, both experimentally and clinically, for the past decade. When the functions of heparin are preserved on the surface, the heparinized surface plays multiple roles in attenuating the systemic inflammatory response. These include the ability to attenuate contact activation, coagulation activation, complement activation and, directly or indirectly, platelet and leukocyte activation. The heparinized surface also renders the cardiopulmonary bypass (CPB) circuits hydrophilic and protein resistant and augments lipoprotein binding. The multifunctional nature of the heparinized surface contributes to the overall biocompatibility of the surface. Clinically, heparin-coated circuits become most effective in reducing systemic inflammatory response and in improving morbidity, mortality, and other patient outcome related parameters when material-independent blood activation is controlled or minimized through a global biocompatibility strategy. Techniques involved in the global biocompatibility strategy are readily available and are being effectively and safely practiced at several centers. With the global biocompatibility strategy, outstanding and reproducible results have been routinely achieved with conventional CPB techniques. Alternative revascularization procedures should equal or surpass conventional CPB, using best clinically proven strategies with respect to patient outcome and long-term graft patency.

Perfusion, Vol. 16, No. 5, 417-428 (2001)
DOI: 10.1177/026765910101600512


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. Sohn, J. Marcoux, T. Mycyk, J. Krahn, and Q. Meng The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress Perfusion, July 1, 2009; 24(4): 231 - 237. [Abstract] [PDF]

				I. Groth, N. Grunewald, and S. Alban Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides - comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea Glycobiology, April 1, 2009; 19(4): 408 - 417. [Abstract] [Full Text] [PDF]

				J. W. Hammon Extracorporeal Circulation: Perfusion System Card. Surg. Adult, January 1, 2008; 3(2008): 350 - 370. [Full Text]

				L. Simonardottir, B. Torfason, E. Stefansson, and J. Magnusson Changes in muscle compartment pressure after cardiopulmonary bypass Perfusion, May 1, 2006; 21(3): 157 - 163. [Abstract] [PDF]

				K. A Samolyk, S. R Beckmann, and R. C Bissinger A new practical technique to reduce allogeneic blood exposure and hospital costs while preserving clotting factors after cardiopulmonary bypass: the Hemobag(R) Perfusion, December 1, 2005; 20(6): 343 - 349. [Abstract] [PDF]

				K. T. Lappegard, J. Riesenfeld, O.-L. Brekke, G. Bergseth, J. D. Lambris, and T. E. Mollnes Differential Effect of Heparin Coating and Complement Inhibition on Artificial Surface-Induced Eicosanoid Production Ann. Thorac. Surg., March 1, 2005; 79(3): 917 - 923. [Abstract] [Full Text] [PDF]

				J.P. Remadi, Z. Rakotoarivello, P. Marticho, F. Trojette, A. Benamar, H. Poulain, and C. Tribouilloy Aortic valve replacement with the minimal extracorporeal circulation (Jostra MECC System) versus standard cardiopulmonary bypass: A randomized prospective trial J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 436 - 441. [Abstract] [Full Text] [PDF]

				K. T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, and T. E. Mollnes Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition Ann. Thorac. Surg., July 1, 2004; 78(1): 38 - 44. [Abstract] [Full Text] [PDF]

				T. N Hoel, V. Videm, S. T Baksaas, T. E Mollnes, F. Brosstad, and J. L Svennevig Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery Perfusion, May 1, 2004; 19(3): 177 - 184. [Abstract] [PDF]

				K. T. Lappegard, M. Fung, G. Bergseth, J. Riesenfeld, J. D. Lambris, V. Videm, and T. E. Mollnes Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation Ann. Thorac. Surg., March 1, 2004; 77(3): 932 - 941. [Abstract] [Full Text] [PDF]

				B. Meng, X. H. Wang, F. Z. Cui, H. Y. Dong, and F. Yu A New Method of Heparinizing PLLA Film by Surface Entrapment Journal of Bioactive and Compatible Polymers, March 1, 2004; 19(2): 131 - 143. [Abstract] [PDF]

				E. A. Hessel II and L. H. Edmunds Jr. Extracorporeal Circulation: Perfusion Systems Card. Surg. Adult, January 1, 2003; 2(2003): 317 - 338. [Full Text]

				V. Vijay and K. McCusker Recent advances in biocompatible surface-modifying additives for cardiopulmonary bypass Perfusion, January 1, 2003; 18(1_suppl): 41 - 45. [PDF]